From recognition to delivery: nucleic acid aptamers in miRNA-related diagnosis and therapy of hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC), the most common primary malignant liver tumour, remains a major clinical challenge because of its low early diagnosis rate and high post-treatment recurrence. MicroRNAs (miRNAs) play key regulatory roles in HCC development and progression and are potential liquid biopsy biomarkers and therapeutic targets. However, the low abundance and instability of miRNAs in body fluids, together with the limitations of conventional detection methods, have hindered their clinical translation. Nucleic acid aptamers, owing to their high affinity, specificity, and ease of chemical modification, are valuable in miRNA-related detection and targeted delivery. This narrative review summarises technical strategies for aptamer-based and aptamer-inspired detection of HCC-associated miRNAs, as well as aptamer-guided miRNA delivery systems in HCC therapy. Importantly, most aptamers used in HCC research do not directly bind miRNAs; instead, they target HCC cells, surface proteins, or exosomes, whereas miRNAs serve as detection analytes or therapeutic cargo. It analyses the design logic and potential integration pathways of “recognition-delivery” platforms, while distinguishing conceptual integration from experimentally validated single-platform systems. Challenges and future directions are also discussed.
Related
- Missed Diagnosis in Alcohol‐Related Hepatocellular Carcinoma: A Call for Alcohol Consumption and Liver Disease Early Detection
- Adherencia a la vigilancia del carcinoma hepatocelular y su asociación con el estadio tumoral al diagnóstico: experiencia de un hospital universitario Adherence to Hepatocellular Carcinoma Surveillance and Its Association with Tumor Stage at Diagnosis: Experience at a University Hospital
- Identification of a G-quadruplex-forming cell-free DNA fragment as a biomarker for the precise diagnosis of hepatocellular carcinoma
- HCC-miR: A Simple, Noninvasive, and Sensitive Model for Early Diagnosis of HCV-Associated Hepatocellular Carcinoma
- Multimodal AI in Hepatocellular Carcinoma: Bridging Diagnosis, Therapy and Prognosis Toward Precision Oncology.
BibTeX
@article{du2026from,
title = {{From recognition to delivery: nucleic acid aptamers in miRNA-related diagnosis and therapy of hepatocellular carcinoma}},
author = {Shihao Du and Shaokang Wu and Ruomiao Li and Jing Du and Huaqiang Liu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.2001917},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.2001917},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From recognition to delivery: nucleic acid aptamers in miRNA-related diagnosis and therapy of hepatocellular carcinoma
AU - Shihao Du
AU - Shaokang Wu
AU - Ruomiao Li
AU - Jing Du
AU - Huaqiang Liu
PY - 2026
DA - 2026/11/04
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.2001917
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.2001917
AB - Hepatocellular carcinoma (HCC), the most common primary malignant liver tumour, remains a major clinical challenge because of its low early diagnosis rate and high post-treatment recurrence. MicroRNAs (miRNAs) play key regulatory roles in HCC development and progression and are potential liquid biopsy biomarkers and therapeutic targets. However, the low abundance and instability of miRNAs in body fluids, together with the limitations of conventional detection methods, have hindered their clinical translation. Nucleic acid aptamers, owing to their high affinity, specificity, and ease of chemical modification, are valuable in miRNA-related detection and targeted delivery. This narrative review summarises technical strategies for aptamer-based and aptamer-inspired detection of HCC-associated miRNAs, as well as aptamer-guided miRNA delivery systems in HCC therapy. Importantly, most aptamers used in HCC research do not directly bind miRNAs; instead, they target HCC cells, surface proteins, or exosomes, whereas miRNAs serve as detection analytes or therapeutic cargo. It analyses the design logic and potential integration pathways of “recognition-delivery” platforms, while distinguishing conceptual integration from experimentally validated single-platform systems. Challenges and future directions are also discussed.
SN - 1663-9812
ER -